Voyager becomes eligible for milestone payment of $5 mln, shares rise

Voyager Therapeutics

26/02/2024 13:02

** Shares of Voyager Therapeutics  VYGR.O  rise 1.1% to
$8.27 premarket
    ** Co says it will receive a milestone payment of $5 mln
from partner Neurocrine Biosciences as it lead candidate goes
into a program evaluating treatments for Friedreich's ataxia
(FA)
    ** The companies expect the program to advance into
first-in-human clinical trials in 2025
    ** FA is a rare inherited disease that causes progressive
damage to your nervous system and movement problems
    ** Under the terms of the companies' 2019 collaboration
agreement, Voyager is eligible to receive up to $1.3 bln in
potential development and commercial milestone payments, tiered
royalties on net sales, and program funding
    ** Up to last close, stock was up 18.2% in the last 12
months

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))